Advertisement

Topics

Latest "Merck Química Argentina S.A.I.C." News Stories

02:44 EDT 23rd September 2018 | BioPortfolio

Here are the most relevant search results for "Merck Química Argentina S.A.I.C." found in our extensive news archives from over 250 global news sources.

More Information about Merck Química Argentina S.A.I.C. on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Merck Química Argentina S.A.I.C. for you to read. Along with our medical data and news we also list Merck Química Argentina S.A.I.C. Clinical Trials, which are updated daily. BioPortfolio also has a large database of Merck Química Argentina S.A.I.C. Companies for you to search.

Showing "Merck mica Argentina" News Articles 1–25 of 3,100+

Friday 21st September 2018

Catabasis to Present New Edasalonexent Clinical Results and Phase 3 Trial Design in Duchenne Muscular Dystrophy

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that the Company will share three presentations, including in the late breaking session, at the 23rd International Congress of the World Muscle Society, being held October 2 – 6, 2018, at the Intercontinental Hotel in Mendoza, Argentina. Presen...


Merck & Co Needs To Go Low On Price For New HIV Drugs In EU

Pifeltro and Delstrigo have been backed for approval by the CHMP but how well they will fare on the market...    

Merck Receives Positive European Agency Opinion for Delstrigo and Pifeltro

The positive opinion was based on findings from two pivotal, randomized, multicenter, double-blind, active controlled Phase 3 trials.Contributed Author: Merck


Pfizer’s Prevnar-13 successor takes aim at Merck rival

Rivals look to broaden coverage across strains

Daiichi, Merck subsidiary partner on breast, lung cancer R&D

Daiichi Sankyo and a subsidiary of Merck, known as MSD outside North America, agreed to work together to develop the former's -More- 

New clinical trial evaluates aesthetic results of conservative surgery in breast cancer

Belén Merck Navarro, Medicine professor at Valencia and Castellón's CEU UCH university is the only Spaniard among the 17 surgeons from 11 different countries that specialize in breast cancer who took part in a clinical trial on the usefulness of 3D images to evaluate the aesthetic results of conservative surgery in breast cancer

Evotec, Bayer oder Merck? Welcher Aktie ich jetzt den Turnaround zutraue

Den Herbst könnte man auch als das Weihnachten der Anleger bezeichnen. In aller Regel ist das die beste Jahreszeit für hochqualitative Schnäppchen. Auch dieses Jahr gibt es wieder genügend Auswahl ...

Thursday 20th September 2018

XOMA Acquires Royalty Interest Position from Agenus on Seven Assets Being Developed by Merck and Incyte

EMERYVILLE, Calif., Sept. 21, 2018 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today that for $15.0 million, it has acquired from Agenus (NASDAQ: AGEN) a partial interest position in the rights to potential milestone and royalty payments associated with seven immuno-oncology antibodies currently being developed by Merck and Incyte under their collaborations with Agenus.    ...

Daiichi Sankyo forms collaboration for Phase lb trial of DS-8201

Daiichi Sankyo Company has signed a clinical trial collaboration agreement with a Merck subsidiary to conduct a Phase lb trial...Read More... The post Daiichi Sankyo forms collaboration for Phase lb trial of DS-8201 appeared first on Drug Development Technology.

Merck Receives Positive CHMP Opinion for DELSTRIGO™ (doravirine/lamivudine/tenofovir disoproxil fumarate) and PIFELTRO™ (doravirine) in the European Union for the Treatment of HIV-1 Infection

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending granting of marketing authorization for two HIV-1 medicines: DELSTRIGO™, a once-daily fixed-dose combination tablet of dorav...

PharmaBlock appoints Dr. Shijie Zhang as Chief Technology Officer

NANJING, China, Sept. 20, 2018 /PRNewswire/ -- PharmaBlock Sciences (Nanjing), Inc. (SZSE: 300725), a global leader in providing innovative chemistry products and services throughout the pharmaceutical R&D process, recently announced the appointment of Dr. Shijie Zhang as Chief Technology Officer. Shijie joins the company from Agios Pharmaceuticals, Inc., where he was Director of Pro...

STAT Plus: Pharmalittle: Merck to halve Keytruda price in China; FDA rejects record number of generic applications

Merck will halve the price of its Keytruda cancer drug for its China launch, following a similar move by Bristol-Myers Squibb.

Merck Publishes Corporate Responsibility Report

Dateline City: KENILWORTH, N.J. Report Illustrates How Merck Creates Sustainable Value for Business and Society KENILWORTH, N.J., Sept. 20, 2018 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today issued its 2017/2018 global Corporate Responsibilit

Pharma depriving developing countries of taxes - report

A damning report by Oxfam claims that pharma giants are ‘depriving’ developing countries of millions of dollars' worth of tax money annually. Oxfam’s report, Prescription for Poverty, slammed Johnson & Johnson, Pfizer, Merck Sharp & Dohme ...

Triple-drug combo pill safe, effective for treatment-naive HIV-1

Merck's single-pill combination drug consisting of doravirine, lamivudine and tenofovir disoproxil fumarate was found to be s -More- 

The Merck Accelerator Program 2019

The Merck Accelerator is looking for real partners so that you can work together in shaping the future. With programs in the headquarters in Germany, in China and the Satellites events in Africa, startups can find their perfect fit and connect to the global network for collaboration. Are you ready to partner with Merck?

Applied DNA Subsidiary, LineaRx, Inc. Signs Joint Development Agreement with Takis and Evvivax to Develop Linear-DNA Based Anti-Cancer Vaccines

Collaboration Seeks to Develop PCR-produced Linear DNA as a Safer Expression Vector for Vaccines Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) announced today that LineaRx, Inc. (“LineaRx”), its wholly-owned

Numab Appoints Immunotherapy Pioneer Ignacio Melero as Scientific Advisor

Company progresses development of tri-specific IO therapeutic ND021 ND021 is designed to improve the risk-benefit profile over conventional IO combination therapies Numab Therapeutics AG, a biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for cancer, today announced it appointed Dr. Ignacio Javi...

Wednesday 19th September 2018

Nosocomial Pneumonia - A Drug Pipeline Analysis Report by Technavio

Technavio has announced their latest drug pipeline analysis report on nosocomial pneumonia. The report includes a comprehensive research on the pipeline molecules under investigation by the pharmaceutical companies within the defined data collection period for the treatment of nosocomial

Merck & Co. to launch Keytruda in China at half of US price: report https://www.firstwordpharma.com/node/1592134  $MRK

Merck & Co. to launch Keytruda in China at half of US price: report https://www.firstwordpharma.com/node/1592134  $MRK

Catabasis Pharmaceuticals to Present New Edasalonexent Clinical Results and Phase 3 Trial Design in Duchenne Muscular Dystrophy at the World Muscle Society Congress

-- Late Breaking Presentation of Data Supporting MRI T2 as a Potential Marker of Clinical Outcome in Duchenne – -- Presentations on MoveDMD Clinical Results and Polaris DMD Phase 3 Design – Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announce

Tuesday 18th September 2018

ICON CEO: CROs Must Be Aware Of Threat Posed By Big Tech

ICON’s CEO Steve Cutler talks candidly about the impact of biotech funding, disruptive tech providers, and the constant pressure of...   

Cancer Vaccine Developer Expands Its Collaboration with Merck

Source: Streetwise Reports   09/19/2018 A Mackie Research Capital report tells how this biotech will benefit from its new and existing programs with this specific partner.In a Sept. 11 research note, Mackie Research Capital analyst Andre Uddin reported that IMV Inc. (IMV:TSX; IMMVD:OTCQX) is again collaborating with Merck, this time evaluating its DPX-Survivac with Mer...

Science Exchange and Clora Announce Partnership to Enable Access to Life Science Expertise

Science Exchange, the world’s leading marketplace for outsourced R&D™, today announced a strategic partnership with Clora, a technology platform that precisely matches

Hemispherx to Distribute Second Lot of Ampligen for use in Multiple Indications in Argentina, the United States and Europe

Hemispherx Biopharma (NYSE:HEB) announced today regulatory inspection and clearance for distribution of the Company’s second commercial scale lot of Ampligen (rintatolimod), which is slated for multiple uses including product launch in Argentina, where Ampligen is approved for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), ME/CFS expanded access program (EAP) in t...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks